(Q43823712)

27 November 2017

title

High dose oral ganciclovir treatment for cytomegalovirus retinitis (English)

1 reference

27 November 2017

0 references

Jacob P Lalezari

1

1 reference

27 November 2017

Dorothy N Friedberg

2

1 reference

27 November 2017

Jack Bissett

3

1 reference

27 November 2017

Michael F Giordano

4

1 reference

27 November 2017

W David Hardy

5

1 reference

27 November 2017

W Lawrence Drew

6

1 reference

27 November 2017

Larry D Hubbard

7

1 reference

27 November 2017

William C Buhles

8

1 reference

27 November 2017

Mary Jean Stempien

9

1 reference

27 November 2017

Panos Georgiou

10

1 reference

27 November 2017

Donald T Jung

11

1 reference

27 November 2017

Charles A Robinson

12

1 reference

27 November 2017

Roche Cooperative Oral Ganciclovir Study Group

13

1 reference

27 November 2017

publication date

1 February 2002

1 reference

Journal of Clinical Virology

27 November 2017

published in

1 reference

27 November 2017

volume

24

1 reference

27 November 2017

issue

1-2

1 reference

27 November 2017

page(s)

67-77

1 reference

Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Acquired immune deficiency syndrome. Ocular manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Treatment of cytomegalovirus retinopathy with ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Cytomegalovirus retinitis and acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Ophthalmic Involvement in Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Nonparametric estimation for the difference or ratio of median failure times.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900229-3

7 January 2021

10.1016/S1386-6532(01)00229-3

Identifiers

DOI

1 reference

27 November 2017

1 reference